Details

Autor(en) / Beteiligte

• Faradji-Hazán, Raquel N
• Valenzuela-Lara, Marisol
• Díaz-Barriga Menchaca, Ana P
• Almeda-Valdes, Paloma
• Antonio-Villa, Neftali E
• Vidrio-Velázquez, Maricela
• Islas-Ortega, Laura
• Martínez-Ramos-Méndez, Angélica
• de la Garza-Hernández, Natalia E
• Bustamante-Martínez, Jorge F
• Sánchez-Ruiz, Karla L
• Yepez-Rodríguez, Alicia E
• González-Gálvez, Guillermo
• Niño-Vargas, Ricardo S
• Sainz de la Maza-Viadero, María E
• Magis-Rodríguez, Carlos

Titel

Type 1 Diabetes Care in Mexico: An Analysis of the RENACED-DT1 National Registry

Ist Teil von

• Revista de investigacion clinica, 2021-05, Vol.73 (4), p.222-230

Ort / Verlag

Mexico: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Erscheinungsjahr

2021

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Information regarding diagnosis, treatment, and follow-up of patients with type 1 diabetes (PWT1D) in Mexico is limited. We developed an on-line platform Registro Nacional de Pacientes con Diabetes Tipo 1 (RENACED-DT1). The objective of the study was to describe the characteristics and healthcare of PWT1D registered in RENACED-DT1. Analyses of 965 PWT1D from July 2014 to January 2018 in different endocrinology clinics around Mexico. Sixty-one percent were female with median age of 21 years, age at diagnosis 11 years, and disease duration at inclusion 8.2 years. Treatment regimen was basal-bolus in 61% and insulin-pumps in 21% (mainly in the private sector); 33.3% with self-monitoring of blood-glucose (SMBG) ≥4 times/day. Mean HbA1c at last follow-up was 8.7 ± 2.1% (72±23 mmol/mol), 18% had HbA1c < 7% (53 mmol/mol), and 35% > 9% (75 mmol/mol). SMBG ≥ 4 times/day was associated with HbA1c < 7%. Time since diagnosis > 10 years, female sex, BMI ≥ 30 kg/m2, SMBG < 4 times/day, and any hypoglycemia were associated with microvascular complications (p < 0.05). Percentage of patients achieving HbA1c < 7% is low; increased blood glucose monitoring is associated with better glycemic control. The achievement of optimal glycemic control must be increased to reduce the incidence of chronic complications and improve quality of life in PWT1D.